Retinoid X Receptors: X-Ploring Their (Patho)Physiological Functions
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Bile Acid Receptor Farnesoid X Receptor: a Novel Therapeutic Target for Metabolic Diseases
Review J Lipid Atheroscler 2017 June;6(1):1-7 https://doi.org/10.12997/jla.2017.6.1.1 JLA pISSN 2287-2892 • eISSN 2288-2561 Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases Sungsoon Fang Severance Biomedical Science Institute, BK21 PLUS project for Medical Science, Yonsei University College of Medicine, Seoul, Korea Bile acid has been well known to serve as a hormone in regulating transcriptional activity of Farnesoid X receptor (FXR), an endogenous bile acid nuclear receptor. Moreover, bile acid regulates diverse biological processes, including cholesterol/bile acid metabolism, glucose/lipid metabolism and energy expenditure. Alteration of bile acid metabolism has been revealed in type II diabetic (T2D) patients. FXR-mediated bile acid signaling has been reported to play key roles in improving metabolic parameters in vertical sleeve gastrectomy surgery, implying that FXR is an essential modulator in the metabolic homeostasis. Using a genetic mouse model, intestinal specific FXR-null mice have been reported to be resistant to diet-induced obesity and insulin resistance. Moreover, intestinal specific FXR agonism using gut-specific FXR synthetic agonist has been shown to enhance thermogenesis in brown adipose tissue and browning in white adipose tissue to increase energy expenditure, leading to reduced body weight gain and improved insulin resistance. Altogether, FXR is a potent therapeutic target for the treatment of metabolic diseases. (J Lipid Atheroscler 2017 June;6(1):1-7) Key Words: Bile acids, Farnesoid X receptor, Metabolic diseases INTRODUCTION of endogenous bile acid nuclear receptor FXR proposes new perspectives to understand molecular mechanisms Bile acids are converted from cholesterol in the liver and physiological roles of bile acids and their receptors by numerous cytochrome P450 enzymes, including in various tissues to maintain whole body homeostasis. -
Retinoic Acid Signaling and Neuronal Differentiation
Cell. Mol. Life Sci. (2015) 72:1559–1576 DOI 10.1007/s00018-014-1815-9 Cellular and Molecular Life Sciences REVIEW Retinoic acid signaling and neuronal differentiation Amanda Janesick • Stephanie Cherie Wu • Bruce Blumberg Received: 23 October 2014 / Revised: 15 December 2014 / Accepted: 19 December 2014 / Published online: 6 January 2015 Ó Springer Basel 2015 Abstract The identification of neurological symptoms cell cycle exit downstream of RA will be critical for our caused by vitamin A deficiency pointed to a critical, early understanding of how to target tumor differentiation. developmental role of vitamin A and its metabolite, reti- Overall, elucidating the molecular details of RAR-regu- noic acid (RA). The ability of RA to induce post-mitotic, lated neurogenesis will be decisive for developing and neural phenotypes in various stem cells, in vitro, served as understanding neural proliferation–differentiation switches early evidence that RA is involved in the switch between throughout development. proliferation and differentiation. In vivo studies have expanded this ‘‘opposing signal’’ model, and the number of Keywords Neurogenesis Á Retinoic acid receptor Á primary neurons an embryo develops is now known to Proliferation-differentiation switch depend critically on the levels and spatial distribution of RA. The proneural and neurogenic transcription factors that control the exit of neural progenitors from the cell Introduction cycle and allow primary neurons to develop are partly elucidated, but the downstream effectors of RA receptor The role of retinoic acid (RA) in neurogenesis has been (RAR) signaling (many of which are putative cell cycle known indirectly for as long as haliver (halibut) and cod liver regulators) remain largely unidentified. -
Detailed Review Paper on Retinoid Pathway Signalling
1 1 Detailed Review Paper on Retinoid Pathway Signalling 2 December 2020 3 2 4 Foreword 5 1. Project 4.97 to develop a Detailed Review Paper (DRP) on the Retinoid System 6 was added to the Test Guidelines Programme work plan in 2015. The project was 7 originally proposed by Sweden and the European Commission later joined the project as 8 a co-lead. In 2019, the OECD Secretariat was added to coordinate input from expert 9 consultants. The initial objectives of the project were to: 10 draft a review of the biology of retinoid signalling pathway, 11 describe retinoid-mediated effects on various organ systems, 12 identify relevant retinoid in vitro and ex vivo assays that measure mechanistic 13 effects of chemicals for development, and 14 Identify in vivo endpoints that could be added to existing test guidelines to 15 identify chemical effects on retinoid pathway signalling. 16 2. This DRP is intended to expand the recommendations for the retinoid pathway 17 included in the OECD Detailed Review Paper on the State of the Science on Novel In 18 vitro and In vivo Screening and Testing Methods and Endpoints for Evaluating 19 Endocrine Disruptors (DRP No 178). The retinoid signalling pathway was one of seven 20 endocrine pathways considered to be susceptible to environmental endocrine disruption 21 and for which relevant endpoints could be measured in new or existing OECD Test 22 Guidelines for evaluating endocrine disruption. Due to the complexity of retinoid 23 signalling across multiple organ systems, this effort was foreseen as a multi-step process. -
Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin
cells Review Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin Agnieszka Bochy ´nska,Juliane Lüscher-Firzlaff and Bernhard Lüscher * ID Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Pauwelsstrasse 30, 52057 Aachen, Germany; [email protected] (A.B.); jluescher-fi[email protected] (J.L.-F.) * Correspondence: [email protected]; Tel.: +49-241-8088850; Fax: +49-241-8082427 Received: 18 January 2018; Accepted: 27 February 2018; Published: 2 March 2018 Abstract: Regulation of gene expression is achieved by sequence-specific transcriptional regulators, which convey the information that is contained in the sequence of DNA into RNA polymerase activity. This is achieved by the recruitment of transcriptional co-factors. One of the consequences of co-factor recruitment is the control of specific properties of nucleosomes, the basic units of chromatin, and their protein components, the core histones. The main principles are to regulate the position and the characteristics of nucleosomes. The latter includes modulating the composition of core histones and their variants that are integrated into nucleosomes, and the post-translational modification of these histones referred to as histone marks. One of these marks is the methylation of lysine 4 of the core histone H3 (H3K4). While mono-methylation of H3K4 (H3K4me1) is located preferentially at active enhancers, tri-methylation (H3K4me3) is a mark found at open and potentially active promoters. Thus, H3K4 methylation is typically associated with gene transcription. The class 2 lysine methyltransferases (KMTs) are the main enzymes that methylate H3K4. KMT2 enzymes function in complexes that contain a necessary core complex composed of WDR5, RBBP5, ASH2L, and DPY30, the so-called WRAD complex. -
Genome-Wide Approach to Identify Risk Factors for Therapy-Related Myeloid Leukemia
Leukemia (2006) 20, 239–246 & 2006 Nature Publishing Group All rights reserved 0887-6924/06 $30.00 www.nature.com/leu ORIGINAL ARTICLE Genome-wide approach to identify risk factors for therapy-related myeloid leukemia A Bogni1, C Cheng2, W Liu2, W Yang1, J Pfeffer1, S Mukatira3, D French1, JR Downing4, C-H Pui4,5,6 and MV Relling1,6 1Department of Pharmaceutical Sciences, The University of Tennessee, Memphis, TN, USA; 2Department of Biostatistics, The University of Tennessee, Memphis, TN, USA; 3Hartwell Center, The University of Tennessee, Memphis, TN, USA; 4Department of Pathology, The University of Tennessee, Memphis, TN, USA; 5Department of Hematology/Oncology St Jude Children’s Research Hospital, The University of Tennessee, Memphis, TN, USA; and 6Colleges of Medicine and Pharmacy, The University of Tennessee, Memphis, TN, USA Using a target gene approach, only a few host genetic risk therapy increases, the importance of identifying host factors for factors for treatment-related myeloid leukemia (t-ML) have been secondary neoplasms increases. defined. Gene expression microarrays allow for a more 4 genome-wide approach to assess possible genetic risk factors Because DNA microarrays interrogate multiple ( 10 000) for t-ML. We assessed gene expression profiles (n ¼ 12 625 genes in one experiment, they allow for a ‘genome-wide’ probe sets) in diagnostic acute lymphoblastic leukemic cells assessment of genes that may predispose to leukemogenesis. from 228 children treated on protocols that included leukemo- DNA microarray analysis of gene expression has been used to genic agents such as etoposide, 13 of whom developed t-ML. identify distinct expression profiles that are characteristic of Expression of 68 probes, corresponding to 63 genes, was different leukemia subtypes.13,14 Studies using this method have significantly related to risk of t-ML. -
Retinoid X Receptor'' B-Mediated TSLP Expression by Κ NF
Comment on ''Cutting Edge: Inhibition of NF- κB-Mediated TSLP Expression by Retinoid X Receptor'' This information is current as Janine Gericke, Anat Gamlieli, Kathrin Weiss and Ralph of September 23, 2021. Rühl J Immunol 2009; 182:3; ; doi: 10.4049/jimmunol.182.1.3-a http://www.jimmunol.org/content/182/1/3.1 Downloaded from References This article cites 3 articles, 2 of which you can access for free at: http://www.jimmunol.org/content/182/1/3.1.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Letters to the Editor 2. Allenby, G., M. T. Saunders, M. Saunders, S. Kazmer, J. Speck, M. Rosenberger, A. Comment on “Cutting Edge: Lovey, P. Kastner, J. F. Grippo, P. Chambon, et al. 1993. Retinoic acid receptors and Inhibition of NF-B-Mediated retinoid X receptors: interactions with endogenous retinoic acids. -
REV-Erbα Regulates CYP7A1 Through Repression of Liver
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/12/13/dmd.117.078105.DC1 1521-009X/46/3/248–258$35.00 https://doi.org/10.1124/dmd.117.078105 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:248–258, March 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics REV-ERBa Regulates CYP7A1 Through Repression of Liver Receptor Homolog-1 s Tianpeng Zhang,1 Mengjing Zhao,1 Danyi Lu, Shuai Wang, Fangjun Yu, Lianxia Guo, Shijun Wen, and Baojian Wu Research Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy (T.Z., M.Z., D.L., S.W., F.Y., L.G., B.W.), and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research (T.Z., B.W.), Jinan University, Guangzhou, China; and School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China (S.W.) Received August 15, 2017; accepted December 6, 2017 ABSTRACT a Nuclear heme receptor reverse erythroblastosis virus (REV-ERB) reduced plasma and liver cholesterol and enhanced production of Downloaded from (a transcriptional repressor) is known to regulate cholesterol 7a- bile acids. Increased levels of Cyp7a1/CYP7A1 were also found in hydroxylase (CYP7A1) and bile acid synthesis. However, the mech- mouse and human primary hepatocytes after GSK2945 treatment. anism for REV-ERBa regulation of CYP7A1 remains elusive. Here, In these experiments, we observed parallel increases in Lrh-1/LRH- we investigate the role of LRH-1 in REV-ERBa regulation of CYP7A1 1 (a known hepatic activator of Cyp7a1/CYP7A1) mRNA and protein. -
Human Retinoic Acid Signaling
RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human Retinoic Acid Signaling Cat. no. 330231 PAHS-180Z For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human Retinoic Acid Pathway RT² Profiler PCR Array profiles the expression of 84 key genes involved in retinoic acid signaling. Retinoic acid (RA) is the primary functional derivative of vitamin A (retinol) and its activity is implicated in many aspects of vertebrate development and homeostasis, while disruptions in this pathway cause developmental abnormalities and disrupt function in adipose, cardiac, nervous, reproductive, and integumentary tissues, among others. RA acts primarily by binding a family of nuclear receptors (the retinoic acid receptors alpha, beta, and gamma) that then heterodimerize with their partners (the retinoid X receptors alpha, beta, and gamma) and alter transcription. -
Signaling by Retinoic Acid in Embryonic and Adult Hematopoiesis
J. Dev. Biol. 2014, 2, 18-33; doi:10.3390/jdb2010018 OPEN ACCESS Journal of Developmental Biology ISSN 2221-3759 www.mdpi.com/journal/jdb/ Review Signaling by Retinoic Acid in Embryonic and Adult Hematopoiesis Elena Cano †, Laura Ariza †, Ramón Muñoz-Chápuli and Rita Carmona * Department of Animal Biology, Faculty of Science, University of Málaga, E29071 Málaga, Spain; E-Mails: [email protected] (E.C.); [email protected] (L.A.); [email protected] (R.M.-C.) † These authors contributed equally to this paper. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +34-952-134-135; Fax: +34-952-131-668. Received: 3 February 2014; in revised form: 5 March 2014 / Accepted: 6 March 2014 / Published: 17 March 2014 Abstract: Embryonic and adult hematopoiesis are both finely regulated by a number of signaling mechanisms. In the mammalian embryo, short-term and long-term hematopoietic stem cells (HSC) arise from a subset of endothelial cells which constitute the hemogenic endothelium. These HSC expand and give rise to all the lineages of blood cells in the fetal liver, first, and in the bone marrow from the end of the gestation and throughout the adult life. The retinoic acid (RA) signaling system, acting through the family of nuclear retinoic acid receptors (RARs and RXRs), is involved in multiple steps of the hematopoietic development, and also in the regulation of the differentiation of some myeloid lineages in adults. In humans, the importance of this RA-mediated control is dramatically illustrated by the pathogeny of acute promyelocytic leukemia, a disease produced by a chromosomal rearrangement fusing the RAR gene with other genes. -
Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases
Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Olivares, Ana Maria, Oscar Andrés Moreno-Ramos, and Neena B. Haider. 2015. “Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases.” Journal of Experimental Neuroscience 9 (Suppl 2): 93-121. doi:10.4137/JEN.S25480. http:// dx.doi.org/10.4137/JEN.S25480. Published Version doi:10.4137/JEN.S25480 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320246 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Journal name: Journal of Experimental Neuroscience Journal type: Review Year: 2015 Volume: 9(S2) Role of Nuclear Receptors in Central Nervous System Running head verso: Olivares et al Development and Associated Diseases Running head recto: Nuclear receptors development and associated diseases Supplementary Issue: Molecular and Cellular Mechanisms of Neurodegeneration Ana Maria Olivares1, Oscar Andrés Moreno-Ramos2 and Neena B. Haider1 1Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA. 2Departamento de Ciencias Biológicas, Facultad de Ciencias, Universidad de los Andes, Bogotá, Colombia. ABSTRACT: The nuclear hormone receptor (NHR) superfamily is composed of a wide range of receptors involved in a myriad of important biological processes, including development, growth, metabolism, and maintenance. -
Pathway Development Via Retinoid X Receptor Vitamin a Enhances In
Vitamin A Enhances in Vitro Th2 Development Via Retinoid X Receptor Pathway This information is current as Charles B. Stephensen, Reuven Rasooly, Xiaowen Jiang, of September 24, 2021. Michael A. Ceddia, Casey T. Weaver, Roshantha A. S. Chandraratna and R. Patterson Bucy J Immunol 2002; 168:4495-4503; ; doi: 10.4049/jimmunol.168.9.4495 http://www.jimmunol.org/content/168/9/4495 Downloaded from References This article cites 40 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/168/9/4495.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 24, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Vitamin A Enhances in Vitro Th2 Development Via Retinoid X Receptor Pathway1 Charles B. Stephensen,2* Reuven Rasooly,* Xiaowen Jiang,* Michael A. Ceddia,3* Casey T. Weaver,† Roshantha A. S. Chandraratna,‡ and R. Patterson Bucy† Vitamin A deficiency diminishes Th2-mediated Ab responses, and high-level dietary vitamin A or treatment with the vitamin A metabolite retinoic acid (RA) enhances such responses. -
TAZORAC® (Tazarotene) Gel 0.05% (Tazarotene) Gel 0.1%
NDA 020600 ® TAZORAC (tazarotene) Gel 0.05% (tazarotene) Gel 0.1% FOR DERMATOLOGIC USE ONLY NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE DESCRIPTION TAZORAC® Gel is a translucent, aqueous gel and contains the compound tazarotene, a member of the acetylenic class of retinoids. It is for topical dermatologic use only. The active ingredient is represented by the following structural formula: O OCH2CH3 N S TAZAROTENE C21H21NO2S Molecular Weight: 351.46 Chemical Name: Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate Contains: Active: Tazarotene 0.05% or 0.1% (w/w) Preservative: Benzyl alcohol 1% (w/w) Inactives: Ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, carbomer 934P, edetate disodium, hexylene glycol, poloxamer 407, polyethylene glycol 400, polysorbate 40, purified water, and tromethamine. CLINICAL PHARMACOLOGY Tazarotene is a retinoid prodrug which is converted to its active form, the cognate carboxylic acid of tazarotene (AGN 190299), by rapid deesterification in animals and man. AGN 190299 (“tazarotenic acid”) binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ, and RARγ but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings is unknown. Psoriasis: The mechanism of tazarotene action in psoriasis is not defined. Topical tazarotene blocks induction of mouse epidermal ornithine decarboxylase (ODC) activity, which is associated with cell proliferation and hyperplasia. In cell culture and in vitro models of skin, tazarotene suppresses expression of MRP8, a marker of inflammation present in the epidermis of psoriasis patients at high levels. In human keratinocyte cultures, it inhibits cornified envelope formation, whose build-up is an element of the psoriatic scale.